Recap: PDL BioPharma Q3 Earnings

Shares of PDL BioPharma PDLI rose 7.96% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 211.11% year over year to ($0.10), which missed the estimate of $0.06.

Revenue of $4,115,000 declined by 90.68% from the same period last year, which missed the estimate of $5,500,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

PDL BioPharma hasn't issued any revenue guidance for the time being.

Technicals

Company's 52-week high was at $3.86

Company's 52-week low was at $2.09

Price action over last quarter: down 17.60%

Company Description

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.